Physician profile
Michael Quinn
NPI 1124059720
$2,891.47
in general payments reported to CMS, 2019-2025
18 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $336 · 2021: $561 · 2022: $614 · 2023: $475 · 2024: $397 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $963.17 | 2019-2025 | Karbinal |
| Glaxosmithkline, LLC. | $379.12 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Corium, LLC | $378.75 | 2022-2025 | Azstarys |
| Pfizer INC. | $273.35 | 2019-2025 | |
| Sanofi Pasteur INC. | $186.59 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $132.00 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $103.10 | 2020-2022 | |
| Sobi, INC | $85.76 | 2020-2023 | |
| Seqirus USA INC | $61.25 | 2022-2025 | Fluad, Flucelvax |
| Adlon Therapeutics L.P. | $54.25 | 2020 | |
| Neos Therapeutics, Lp | $50.80 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.84 | 2023-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Hologic Sales and Service, LLC | $46.20 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.10 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $33.44 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $24.81 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $21.26 | 2024 | Flumist Quadrivalent |
| Cumberland Pharmaceuticals, INC. | $13.68 | 2025 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.